India looking beyond US for pharma exports amid tariff tensions

India is strategically diversifying its pharmaceutical exports beyond the U.S., its largest market ($10.5 billion in FY25), to semi-regulated markets in Africa, Latin America, and Southeast Asia, driven by concerns over potential U.S. tariffs. Concurrently, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) aims to boost finished goods sales to China to mitigate the substantial $99.2 billion trade deficit, despite India's high reliance on Chinese raw materials. This initiative reflects a proactive effort to de-risk market concentration and rebalance key trade relationships.

Analysis

India's pharmaceutical sector is executing a strategic pivot to mitigate concentration risk and geopolitical tensions, primarily driven by the threat of potential U.S. tariffs. While the U.S. remains the largest export destination, accounting for over a third of shipments and growing 20% to $10.5 billion in fiscal 2025, the industry's trade body, Pharmexcil, identifies this dependence as a significant concern. The diversification strategy targets semi-regulated markets in Africa, Latin America, and Southeast Asia to create new revenue streams. Concurrently, there is a concerted effort to increase exports of finished pharmaceutical goods to China, with a stated goal of generating $6 billion to help address India's $99.2 billion trade deficit with the country. This China-focused initiative is notably complex, given that the Indian pharma industry imports over 60% of its active pharmaceutical ingredients (APIs) and raw materials from China, creating a delicate supply chain interdependency that could influence both production costs and trade negotiations.

Key Decisions for Investors

• Investors should re-evaluate holdings in Indian pharmaceutical companies based on their respective revenue concentrations in the U.S. market, as firms with heavy exposure face heightened risk from potential tariff actions.
• Monitor companies for tangible progress in penetrating new semi-regulated markets in Africa, Latin America, and Southeast Asia, as success in these regions could serve as a key long-term growth driver and a hedge against U.S. market volatility.
• Closely track the dual-edged relationship with China, paying attention to both the potential upside from increased finished goods exports and the significant risk of API supply chain disruptions or cost inflation, which could impact margins across the entire sector.